Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q12889
UPID:
OVGP1_HUMAN
Alternative names:
Estrogen-dependent oviduct protein; Mucin-9; Oviductal glycoprotein; Oviductin
Alternative UPACC:
Q12889; A0AV19; B9EGE1; Q15841
Background:
Oviduct-specific glycoprotein, also known as Estrogen-dependent oviduct protein, Mucin-9, Oviductal glycoprotein, or Oviductin, plays a crucial role in reproductive biology. It binds to oocyte zona pellucida in vivo, suggesting its involvement in the fertilization process and possibly early embryonic development.
Therapeutic significance:
Understanding the role of Oviduct-specific glycoprotein could open doors to potential therapeutic strategies, particularly in the realm of fertility treatments and reproductive health.